Revtorpyk Injection, Powder, For Solution
Product Images NDC 84577-751

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Revtorpyk (NDC 84577-751). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celcuity Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Revtorpyk 01)

Chemical structure of gedatolisib, the active ingredient in REVTORPYK 180 mg injection powder for solution, shown as a detailed molecular diagram with labeled rings and functional groups.*

FDA Label Image

Figure 1 (Revtorpyk 02)

A Kaplan-Meier survival curve chart depicting progression-free survival (%) over 24 months. It compares the combination treatment of REVTORPYK plus Fulvestrant and Palbociclib to Fulvestrant alone, showing higher survival percentages for the combination therapy. The chart includes censored data points and a table of subjects at risk for each group over time.*

FDA Label Image

Figure 2 (Revtorpyk 03)

A Kaplan-Meier curve showing progression-free survival (%) over time in months for two groups: REVTORPYK plus Fulvestrant and Fulvestrant alone. The graph includes censored data points and a table of subjects at risk corresponding to each time point up to 26 months. The curve for REVTORPYK plus Fulvestrant shows higher progression-free survival rates compared to Fulvestrant alone.*

FDA Label Image

Principal Display Panel – Carton (NDC 84577-751-01)

Packaging label for REVTORPYK 180 mg/vial injection powder for solution, containing active ingredient gedatolisib. Designed for intravenous infusion after reconstitution and dilution. Label includes directions for reconstitution with sterile water and dilution with Dextrose Injection, storage instructions at 20°C to 25°C, and manufacturer details as Celcuity Inc., Minneapolis, MN. Single-dose vial, discard unused portion.*

FDA Label Image

Principal Display Panel – Vial Label (NDC 84577-751-01)

Label for REVTORPYK 180 mg/vial (gedatolisib) injection, powder for solution for intravenous use. The single-dose vial is for intravenous infusion after reconstitution and dilution. Manufactured for Celcuity Inc., Minneapolis, MN. Label includes dosage, storage instructions, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.